These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 11363810)

  • 1. Antiretrovirals plus immunomodulators: didanosine/interferon-alpha combination shows promise.
    Folkers G
    NIAID AIDS Agenda; 1996 Jun; ():8-9. PubMed ID: 11363810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with didanosine and interferon-alpha in human immunodeficiency virus-infected patients: results of a phase I/II trial.
    Kovacs JA; Bechtel C; Davey RT; Falloon J; Polis MA; Walker RE; Metcalf JA; Davey V; Piscitelli SC; Baseler M; Dewar R; Salzman NP; Masur H; Lane HC
    J Infect Dis; 1996 Apr; 173(4):840-8. PubMed ID: 8603961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
    Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ddI plus d4T.
    James JS
    AIDS Treat News; 1996 Sep; (No 254):4. PubMed ID: 11363818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies of zidovudine in combination with didanosine and zalcitabine.
    Jablonowski H
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150 x 10(6)/L: results of the Zidon trial. Zidon Study Group.
    Fernández-Cruz E; Lang JM; Frissen J; Furner V; Châteauvert M; Boucher CA; Dowd P; Stevens J
    AIDS; 1995 Sep; 9(9):1025-35. PubMed ID: 8527074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: AIDS Clincal Trial Group 068.
    Mildvan D; Bassiakos Y; Zucker ML; Hyslop N; Krown SE; Sacks HS; Zachary J; Paredes J; Fessel WJ; Rhame F; Kramer F; Fischl MA; Poiesz B; Wood K; Ruprecht RM; Kim J; Grossberg SE; Kasdan P; Bergé P; Marshak A; Pettinelli C
    Antivir Ther; 1996 Apr; 1(2):77-88. PubMed ID: 11321183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Researchers are rethinking role of AZT in drug therapy.
    AIDS Policy Law; 1995 Oct; 10(18):11. PubMed ID: 11362821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CPCRA 007: preliminary results of combination antiretroviral study.
    Randall P
    NIAID AIDS Agenda; 1996 Mar; ():2. PubMed ID: 11363796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACTG 175: new insights into treating patients with intermediate-stage HIV disease.
    Folkers G
    NIAID AIDS Agenda; 1995 Dec; ():4-5. PubMed ID: 11363352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Alpha trial: European/Australian randomized double-blind trial of two doses of didanosine in zidovudine-intolerant patients with symptomatic HIV disease. Alpha International Coordinating Committee.
    AIDS; 1996 Jul; 10(8):867-80. PubMed ID: 8828744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II controlled study of a combination of the immune modulator, lentinan, with didanosine (ddI) in HIV patients with CD4 cells of 200-500/mm3.
    Gordon M; Guralnik M; Kaneko Y; Mimura T; Goodgame J; DeMarzo C; Pierce D; Baker M; Lang W
    J Med; 1995; 26(5-6):193-207. PubMed ID: 8721897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AZT studies reinforce benefits of combination.
    AIDS Alert; 1995 Jan; 10(1):11-2. PubMed ID: 11362167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. AI 454-146 Team.
    Monno L; Cargnel A; Soranzo ML; Chirianni A; Ferraro T; Di Stefano M; Angarano G
    Antivir Ther; 1999; 4(4):195-202. PubMed ID: 10723498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New double vs. triple antiviral combination study, CD4 200-500, no prior treatment.
    James JS
    AIDS Treat News; 1995 Dec; (no 236):7. PubMed ID: 11363052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307.
    Frank I; Bosch RJ; Fiscus S; Valentine F; Flexner C; Segal Y; Ruan P; Gulick R; Wood K; Estep S; Fox L; Nevin T; Stevens M; Eron JJ;
    AIDS Res Hum Retroviruses; 2004 Sep; 20(9):916-26. PubMed ID: 15597521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nevirapine triple combo results released.
    Common Factor; 1995 Apr; (no 10):21. PubMed ID: 11362346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of interferon alpha therapy for HIV type 1 infection.
    Haas DW; Lavelle J; Nadler JP; Greenberg SB; Frame P; Mustafa N; St Clair M; McKinnis R; Dix L; Elkins M; Rooney J
    AIDS Res Hum Retroviruses; 2000 Feb; 16(3):183-90. PubMed ID: 10710206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerance of a triple combination therapy with zidovudine, didanosine and interferon-alpha in seven HIV-infected patients.
    Bissuel F; Trabaud MA; Leriche K; Cotte L; Schlienger I; Rougier P; Trepo C
    AIDS; 1995 Nov; 9(11):1285. PubMed ID: 8561983
    [No Abstract]   [Full Text] [Related]  

  • 20. Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus.
    Klein MB; Campeol N; Lalonde RG; Brenner B; Wainberg MA
    AIDS; 2003 May; 17(7):1001-8. PubMed ID: 12700449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.